ArticleCureus2025
Ultrasound-Assisted Catheter-Directed Thrombolysis in Pulmonary Embolism: A Case Series.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary embolism (PE) is a life-threatening condition associated with significant morbidity and mortality. While systemic thrombolysis is effective in high-risk cases, it carries a substantial risk of bleeding complications. Ultrasound-assisted catheter-directed thrombolysis (UCDT) has emerged as a promising alternative, enhancing clot resolution while minimizing hemorrhagic risks. This case series presents three patients with high-risk and intermediate-high-risk PE who underwent UCDT. All patients exhibited hemodynamic instability and right ventricular dysfunction. Following UCDT, significant clinical and echocardiographic improvements were observed, with no major bleeding complications. UCDT represents a targeted thrombolysis approach that optimizes clot dissolution while reducing systemic thrombolytic exposure. Current evidence supports UCDT as an effective and safer alternative for select PE patients, though further randomized studies are needed to refine patient selection and standardize treatment protocols. This case series highlights the clinical benefits of UCDT and reinforces its role as a viable treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.